Evidence map›Paper›PMID 35547856›Full record

ArticleJournal of men's health2022

Amarnath Mukherjee, Augene Park, Kelvin Paul Davies

Open access · goldAbstract read
In one paragraph

Article in Journal of men's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amarnath MukherjeeDepartment of Urology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Augene ParkDepartment of Urology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Kelvin Paul DaviesDepartment of Urology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Albert Einstein College of Medicine · US

Funding

X-RAY STRUCTURE OF RIFM PROTEIN FROM THE BIOSYNTHESIS PATHWAY OF THE ANSAMYCIN AP41RR012408 · NCRR · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI MARIUZZA, ROY A · 1998 to 2011
$32.2M
Rutgers Biotechnology Training ProgramT32GM135141 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI ANN M. STOCK, Martin L Yarmush · 2020 to 2026
$3.5M
Opiorphin as a master regulator of pathways leading to priapismR01DK107807 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DAVIES, KELVIN P · 2016 to 2020
$2.4M
The microtubule cytoskeleton as a novel target for cavernous nerve regeneration after prostatectomyR01DK109314 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DAVIES, KELVIN P, SHARP, DAVID JAMES · 2017 to 2020
$2.3M
NCRR NIH HHS P41 RR012408NIDDK NIH HHS R01 DK107807NIDDK NIH HHS R01 DK109314NIGMS NIH HHS T32 GM135141
6 · The paper itself

Abstract

Background and objective: A growing body of literature suggests modulated expression of members of the opiorphin family of genes ( Material and methods: We engineered knock-out of the opiorphin gene, Results: The present studies demonstrate that LNCaP cell-lines with consisitutive knock-out of Conclusion: Overall, our studies add to the growing body of evidence that opiorphin-encoding genes play a role in cancer development and progression.

Indexed as

Cell invasivenessCell motilityOpiorphinPROL1Prostate cancer

Identifiers

PMID35547856
PMCPMC9089447
OpenAlexW3205105991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.